With 56239.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.275 whereas the lowest price it dropped to was $2.2193. The 52-week range on SEER shows that it touched its highest point at $2.62 and its lowest point at $1.56 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 1.57.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SEER was up-trending over the past week, with a rise of 10.19%, but this was up by 6.07% over a month. The stock lost -1.73% in the past year, while it has gained 34.32% so far this year. A look at the trailing 12-month EPS for SEER yields -1.41 with Next year EPS estimates of -0.91. For the next quarter, that number is -0.37. This implies an EPS growth rate of 13.58% for this year and 24.64% for next year. EPS is expected to grow by 16.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -39.46%.
Float and Shares Shorts:
At present, 55.39 million SEER shares are outstanding with a float of 32.10 million shares on hand for trading. On 2025-06-13, short shares totaled 1.78 million, which was 302.99999 higher than short shares on 1747267200. In addition to Dr. Omid C. Farokhzad M.D., Ph.D. as the firm’s Founder, CEO, & Chair of the Board of Directors, Mr. David R. Horn serves as its President,Treasurer & CFO.
Institutional Ownership:
Through their ownership of 0.67813003 of SEER’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SEER reported revenue of $4145000.0 and operating income of -$20731000.0. The EBITDA in the recently reported quarter was -$19133000.0 and diluted EPS was -$0.34.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SEER since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.39345 being high and -$1.41321 being low. For SEER, this leads to a yearly average estimate of -$1.40333. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.34. The average estimate for the next quarter is thus -$0.27.
